GlassScriptPhysician profile
Camille Mason
NPI 1821063678
$2,653.96
in general payments reported to CMS, 2019-2025
14 companies · $563 in 2025
The $563 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $372 · 2021: $221 · 2022: $409 · 2023: $310 · 2024: $534 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.78 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.14 | 2019-2025 | |
| Ucb, INC. | $401.79 | 2019-2025 | Cimzia, Bimzelx |
| Leo Pharma INC. | $390.98 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $213.60 | 2020-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $208.77 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $208.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $141.87 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.94 | 2019-2024 | Siliq, Duobrii, Targretin |
| Prugen, INC. Pharmaceuticals | $47.48 | 2019 | |
| Amgen INC. | $47.43 | 2020-2024 | Otezla |
| Pfizer INC. | $43.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.67 | 2023 | Libtayo |
| Sanofi-Aventis U.S. LLC | $27.51 | 2019 | |
| Lilly USA, LLC | $18.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.